| Title |
Interleukin 2 in the Pathogenesis and Therapy of Type 1 Diabetes
|
|---|---|
| Published in |
Current Diabetes Reports, October 2014
|
| DOI | 10.1007/s11892-014-0553-6 |
| Pubmed ID | |
| Authors |
Michelle Rosenzwajg, Guillaume Churlaud, Agnès Hartemann, David Klatzmann |
| Abstract |
Regulatory T cells (Tregs) play a major role in controlling effector T cells (Teffs) responding to self-antigens, which cause autoimmune diseases. An improper Treg/Teff balance contributes to most autoimmune diseases, including type 1 diabetes (T1D). To restore a proper balance, blocking Teffs with immunosuppressants has been the only option, which was partly effective and too toxic. It now appears that expanding/activating Tregs with low-dose interleukin-2 (IL-2) could provide immunoregulation without immunosuppression. This is particularly interesting in T1D as Tregs from T1D patients are reported as dysfunctional and a relative deficiency in IL-2 production and/or IL-2-mediated signaling could contribute to this phenotype. A clinical study of low-dose IL-2 showed a very good safety profile and good Treg expansion/activation in T1D patients. This opens the way for efficacy trials to test low-dose IL-2 in prevention and treatment of T1D and to establish in which condition restoration of a proper Treg/Teff balance would be beneficial in the field of autoimmune and inflammatory diseases. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 2% |
| Unknown | 54 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 16% |
| Student > Bachelor | 8 | 15% |
| Researcher | 7 | 13% |
| Student > Master | 5 | 9% |
| Other | 4 | 7% |
| Other | 12 | 22% |
| Unknown | 10 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 22% |
| Biochemistry, Genetics and Molecular Biology | 8 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 13% |
| Immunology and Microbiology | 7 | 13% |
| Agricultural and Biological Sciences | 4 | 7% |
| Other | 7 | 13% |
| Unknown | 10 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 October 2014.
All research outputs
#18,381,794
of 22,768,097 outputs
Outputs from Current Diabetes Reports
#772
of 1,006 outputs
Outputs of similar age
#186,164
of 260,259 outputs
Outputs of similar age from Current Diabetes Reports
#11
of 13 outputs
Altmetric has tracked 22,768,097 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,006 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,259 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.